- Home
- FBRX vs LXEO Comparison
FBRX vs LXEO Comparison
Compare FBRX & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBRX | LXEO |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.2M | 418.9M |
| IPO Year | 2017 | 2023 |
Fundamental Metrics
Financial Performance| Metric | FBRX | LXEO |
|---|---|---|
| Price | $27.32 | $5.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $67.00 | $18.44 |
| AVG Volume (30 Days) | 385.9K | ★ 835.2K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.30 | 39.81 |
| EPS | N/A | ★ N/A |
| Revenue | $36,000.00 | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.50 | $2.43 |
| 52 Week High | $35.80 | $10.99 |
Technical Indicators
Market Signals| Indicator | FBRX | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 42.45 |
| Support Level | $26.67 | $4.95 |
| Resistance Level | $31.71 | $6.08 |
| Average True Range (ATR) | 3.16 | 0.41 |
| MACD | -0.26 | -0.01 |
| Stochastic Oscillator | 20.92 | 20.14 |
Price Performance
Historical ComparisonAbout FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.